Aegera Therapeutics Inc.

Development of novel anti-cancer therapies based on apoptosis

Aegera Therapeutics is a privatly held oncology company, which evolved from a merger of Apoptogen and Exogen Neuroscience in 2000. A three-year licensing and collaboration agreement of about US $25 MM with Curis Inc. assures the research in the area of adult human stem cells. Aegera formed its wholly owned subsidiary Aegera Oncology.

Michael J. Berendt, Ph.D.,
President & Chief Executive Officer
Donald Olds, M.Sc., MBA, CFO
Jon Durkin, PhD, VP Drug Discovery & Preclinical Development
John Gillard, PhD, Executive VP & CSO
Jacques Jolivet, VP Clinical

Perry Molinoff, Ph.D., Chairman
Philip Barker, Ph.D.
Charlie Fong, Ph.D.
Luc Marengère, Ph.D.
William P. Peters, M.D., Ph.D., M.B.A.
Lennie Ryer

Philip Barker, Ph.D.
David Kaplan, Ph.D.
Robert Korneluk, Ph.D.
Alex MacKenzie, Ph.D.
Freda Miller, Ph.D.

810 chemin du Golf
Nun’s Island (Montreal)
Quebec, H3E 1A8
Canada
Phone +1-514-288-5532
Fax: +1-514-288-9280

Besides Aegera’s lead oncology programmes Aegera is also involved in patnerships and collaborations to investigate the potential of cell based therapies.

A Phase 1b trial of AEG35156 XIAP Antisense is currently in process in the UK.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.